reports
Nyxoah to Participate in the Jefferies Global Healthcare Conference
Nyxoah to Participate in the Jefferies Global Healthcare Conference Nyxoah to Participate in the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – June 3, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 5 – 6, 2024 in New York. Olivier Taelman, Nyxoah’s Chi...
Nyxoah Participera à la Conférence Jefferies Global Healthcare
Nyxoah Participera à la Conférence Jefferies Global Healthcare Nyxoah Participera à la Conférence Jefferies Global Healthcare Mont-Saint-Guibert, Belgique – 3 juin 2024, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») opère dans le secteur des technologies médicales et se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La Société a annoncé aujourd’hui qu’elle participera à la conférence Jefferies Global Healthcare Conference, qui a lieu ...
Information on the total number of voting rights and shares
Information on the total number of voting rights and shares REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 3, 2024, 10:15 pm CET / 4:15 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,902,793.43 Total number of securities carrying voting rights: 34,360,390 (all ordinary shares) Total number of voting rights (= denominator): ...
Informations sur le nombre total de droits de vote et d'actions
Informations sur le nombre total de droits de vote et d'actions INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 3 juin 2024, 22:15h CET / 16:15h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH)publie les informations ci-dessous suite à l'émission de nouvelles actions. Capital: EUR 5.902.793,43 Nombre total de titres avec droits de vote: 34.360.390 (tous des actions ordinaires) Nombre total de droits d...
Publication relating to transparency notifications
Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received four transparency notifications as detailed below. FMR LLC On May 30, 2024, Nyxoah received a transparency notification from FMR LLC following the crossing above the 3% threshold on May 28, 2024. As of such date, FMR LL...
Publication relative à des notifications de transparence
Publication relative à des notifications de transparence INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 3 juin 2024, 22:05h CET / 16:05h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu quatre notifications de transparence comme détaillé ci‑dessous. FMR LLC Le 30 mai 2024, Nyxoah a reçu une notification de transparence de FMR LLC suivant le franchissement du seuil de 3% en date du 28 mai 202...
Nyxoah Announces Closing of Offering and Partial Exercise of Option to...
Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces Closing of Offering and Partial Exercise ofOption to Purchase Additional Shares Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced underwritten public ...
- Laura Roba
Nyxoah - USD 52.5m raised to support US launch
• Nyxoah successfully raised USD 52.5m via an underwritten public offering in the US, which included shares sold in a private offering to certain qualified or institutional investors outside the US, including within the EU. 5.4m new shares have been issued at a 8.5% discount to the last closing price before the announcement• The option to purchase additional shares was partially exercised with 300k additional shares purchased out of the 800k initially offered• This raise was expected as manageme...
Information on the Total Number of Voting Rights and Shares
Information on the Total Number of Voting Rights and Shares REGULATED INFORMATION Information on the Total Number of Voting Rights and Shares Mont-Saint-Guibert (Belgium), May 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,851,253.43 Total number of securities carrying voting rights: 34,060,390 (all ordinary shares) Total number of voting rights (= denominator): 34,...
Informations sur le Nombre Total de Droits de Vote et d'Actions
Informations sur le Nombre Total de Droits de Vote et d'Actions INFORMATION RÉGLEMENTÉE Informations sur le Nombre Total de Droits de Vote et d'Actions Mont-Saint-Guibert (Belgique), le 28 mai 2024, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH)publie les informations ci-dessous suite à l'émission de nouvelles actions. Capital: EUR 5.851.253,43 Nombre total de titres avec droits de vote: 34.060.390 (tous des actions ordinaires) Nombre total de droits d...
- Laura Roba
Nyxoah - Raising USD 50m
Nyxoah announced a USD 50m capital raise via an underwritten public offering in the US, which includes shares sold in a private offering to certain qualified or institutional investors outside the US, including within the EU.Shares will be sold at a 5% discount to the closing price on Wednesday. The offering is expected to close on May 28, 2024.Based on upcoming news flow and our belief in the competitive edge of the Genio System over existing HGNS devices, we reiterate our BUY rating.
Nyxoah Announces Pricing of Offering
Nyxoah Announces Pricing of Offering REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Announces Pricing of Offering Mont-Saint-Guibert, Belgium – May 23, 2024, 3:50 pm CET / 9:50 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the pricing of an underwritten public offering in the United States, which includes shares sold in a private offering to certain qualified or institutional investors outside th...
Nyxoah Annonce la Fixation du Prix de l'Offre
Nyxoah Annonce la Fixation du Prix de l'Offre INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Nyxoah Annonce la Fixation du Prix de l'Offre Mont-Saint-Guibert, Belgique – 23 mai 2024, 15h50 CET / 9h50 ET - Nyxoah SA (Euronext Brussels/ Nasdaq : NYXH) ("Nyxoah" ou la "Société") opère dans le secteur des technologies médicales et se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La Société a annoncé aujourd'hui la fixation du prix d'une offre publique souscrite aux États-Unis qui pour...
Nyxoah Announces Reduction of the Maximum Amount Available Under its A...
Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – May 22, 2024, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today that it has reduced the maximum amount ...
Nyxoah Announces Proposed Offering of Ordinary Shares
Nyxoah Announces Proposed Offering of Ordinary Shares REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Announces Proposed Offering of Ordinary Shares Mont-Saint-Guibert, Belgium – May 22, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a private offering to certain qu...
Nyxoah Annonce une Proposition d'Offre d'Actions Ordinaires
Nyxoah Annonce une Proposition d'Offre d'Actions Ordinaires INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Nyxoah Annonce une Proposition d'Offre d'Actions Ordinaires Mont-Saint-Guibert, Belgique – 22 mai 2024, 22h05 CET / 16h05 ET - Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) ("Nyxoah" ou la "Société") opère dans le secteur des technologies médicales et se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La Société a annoncé aujourd'hui le lancement d'une proposition d'offre publiqu...
- Laura Roba
Nyxoah - Q1 in line with expectations
Nyxoah published its Q1 24 results. Revenues were in line with CSS, up 177% YoY. Remember that management guided for a 25% decline in Q1 sales following a seasonality effect in Q4. We should also see more effects from the ResMed partnership as of H2.Stock has been hit recently as the market awaits a capital raise. Management previously indicated that they would raise capital on the back of the DREAM trial results Yet, the company still has cash until the end of the year. Next key catalyst is of ...
Nyxoah Reports First Quarter 2024 Financial and Operating Results
Nyxoah Reports First Quarter 2024 Financial and Operating Results REGULATED INFORMATION Nyxoah Reports First Quarter 2024 Financial and Operating ResultsAnnounced DREAM U.S. pivotal study achieved primary endpoints On track for FDA approval as early as end of 2024 Mont-Saint-Guibert, Belgium – May 14, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results ...
Nyxoah Présente ses Résultats Financiers et Opérationnels pour le Pre...
Nyxoah Présente ses Résultats Financiers et Opérationnels pour le Premier Trimestre 2024 INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et Opérationnels pour le Premier Trimestre 2024L'étude pivot DREAM U.S. annoncée a atteint les critères d'évaluation primairesEn bonne voie pour être approuvé par la FDA dès la fin de l'année 2024 Mont-Saint-Guibert, Belgique – 14 mai 2024, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») opère dans le secteur des technologies médicales et se concentre sur le développement et la commer...
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter 2024 on Tuesday, May 14, 2024, after market close. Company management will host a ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.